ABM Therapeutics Announces US FDA Orphan Drug Designation to ABM-1310

ABM Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310, an innovative small molecule BRAF inhibitor. This designation is specifically intended for the treatment of individuals afflicted by glioblastoma (GBM) and who carry the BRAF V600 mutation. ABM-1310 is an orally administered medication with remarkable characteristics. It boasts high selectivity for BRAF mutations, excellent water solubility, and an ability to effectively permeate the blood-brain barrier. Currently, ABM-1310 is undergoing Phase I clinical trials at multiple medical sites across the United States and China. ABM-1310 has exhibited strong potential as an anticancer agent, while also demonstrating a favourable safety profile in patients with advanced BRAF V600 mutant solid tumours, including brain tumours like GBM and other gliomas. Promising results have emerged from the interim findings of the U.S. Phase I study. Glioblastoma (GBM) is exceptionally challenging and aggressive brain tumour to manage. Its intricate tumorigenesis and resistance to standard therapies contribute to the complexity of treatment. Conventional approaches like surgical resection, radiation, and chemotherapy have shown limited efficacy. With few treatment options available after the disease has progressed, the development of more effective treatments is in high demand.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!